LinusBio and Coralis Partner to Reduce Autism Diagnosis Waitlists

On Aug 6, 2025

LinusBio, a leader in precision exposome medicine based in North Brunswick, and Coralis Health, a pioneering virtual care platform for neurodivergent children and families, have announced a  partnership to provide end-to-end diagnostic services for autism spectrum disorder (ASD). This collaboration combines LinusBio’s ClearStrand-ASD™ biomarker test with Coralis Health’s specialized care platform, creating a seamless pathway from early screening to diagnosis and intervention.

The partnership addresses a critical gap in autism diagnosis and care by connecting families who receive ClearStrand-ASD results indicating potential autism risk directly to Coralis Health’s network of specialized clinicians and diagnostic services, dramatically reducing the typical years-long diagnostic journey to just 90 days. Once ClearStrand results are available, LinusBio directly refers qualifying families to Coralis Health, with virtual diagnostic teams reaching out within five calendar days to schedule intake appointments and complete comprehensive evaluations within 90 days.

The integrated service is designed primarily for families who have concerns about their child’s development and are seeking both objective screening insights and expert diagnostic evaluation. Healthcare and service providers can also leverage this streamlined pathway to offer their patients a comprehensive diagnostic solution that reduces referral complexity and wait times for specialized autism evaluations.

“This partnership represents exactly the kind of innovation needed to transform autism care,” said Dr. Manish Arora, founder and CEO of LinusBio. “ClearStrand-ASD provides families with crucial early insights, but we recognized that many families needed additional support navigating the next steps. By partnering with Coralis Health, we’re creating a comprehensive solution that takes families from screening through diagnosis and into intervention—all through a single, coordinated pathway.”

“Our goal has always been to make sure that children are connected to life-changing therapies in a timely manner, while providing the highest quality care. We also want to reduce the burden on clinicians, by finding ways to standardize care in a space that’s currently too dependent on individual clinical expertise and training,” explained Dr. Ayesha Cheema-Hasan, founder and CEO of Coralis Health. “By leveraging technology thoughtfully, we aim to bridge the gap in access, and ensure that every child has the opportunity to thrive regardless of where they start.”

The integrated service provides families with a complete diagnostic solution, from initial biomarker screening through comprehensive autism evaluation. Coralis Health’s diagnostic team conducts thorough assessments using clinically validated tools, delivering detailed diagnostic reports that families can use to access essential services and interventions. The service is available for children 16 months and older, with younger children who complete ClearStrand testing receiving a credit toward future diagnostic evaluation once they meet the age requirement.

The ClearStrand-ASD and diagnostic evaluation solution is now available in 11 states; Alaska, Colorado, Connecticut, Illinois, Maryland, North Carolina, Rhode Island, Tennessee, Virginia, Washington and Washington, D.C. Families who receive ClearStrand-ASD results indicating potential autism risk will have direct access to Coralis Health’s diagnostic services.

To access more business news, visit NJB News Now.

Related Articles: